» Articles » PMID: 32441178

Methamphetamine Use and Its Correlates Among Individuals with Opioid Use Disorder in a Midwestern U.S. City

Overview
Publisher Informa Healthcare
Date 2020 May 23
PMID 32441178
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

: U.S. is experiencing a surging trend of methamphetamine use among individuals who use opioids. More research is needed to characterize this emerging "twin epidemic." The study aims to identify social and behavioral characteristics associated with methamphetamine use among individuals with opioid use disorder (OUD) in the Dayton, Ohio, area, an epicenter of the opioid crisis and an emerging frontier of methamphetamine epidemic. 357 adult individuals with current OUD were recruited using targeted and respondent-driven sampling. Structured interviews collected information on social and drug use characteristics. Multivariable Logistic Regression was used to identify characteristics associated with the past 6-month use of methamphetamine. 49.7% were female, and 88.8% were non-Hispanic whites. 55.6% used methamphetamine in the past 6-months, and 84.9% reported first use of methamphetamine after initiation of illicit opioids. Methamphetamine use was associated with homelessness (aOR = 2.46,  = .0001), lifetime history of diverted pharmaceutical stimulant use (aOR = 2.97,  < .001), injection route of heroin/fentanyl use (aOR = 1.89,  = .03), preference for fentanyl over heroin (aOR = 1.82,  = .048), lifetime history of extended-release injectable naltrexone (Vivitrol)-based treatment (aOR = 2.89,  = .003), and more frequent marijuana use (aOR = 1.26,  = .04). The findings point to the complexity of motivational and behavioral pathways associated with methamphetamine and opioid co-use, ranging from self-treatment and substitution behaviors, attempts to endure homelessness, and greater risk taking to experience euphoria. More research is needed to understand the causal relationships and the association between methamphetamine and Vivitrol use. Public health responses to the opioid crisis need to be urgently expanded to address the growing epidemic of methamphetamine use.

Citing Articles

Naloxone administration and survival in overdoses involving opioids and stimulants: An analysis of law enforcement data from 63 Pennsylvania counties.

Cano M, Jones A, Silverstein S, Daniulaityte R, LoVecchio F Int J Drug Policy. 2024; 135():104678.

PMID: 39637491 PMC: 11724750. DOI: 10.1016/j.drugpo.2024.104678.


Appalachia - Bridging the Opioid Epidemic Amid the Fentanyl Crisis.

Ann Fecci T Linacre Q. 2024; 91(4):353-372.

PMID: 39429755 PMC: 11489903. DOI: 10.1177/00243639241245103.


Naloxone Administration and Survival in Overdoses Involving Opioids and Stimulants: An Analysis of Law Enforcement Data from 63 Pennsylvania Counties.

Canoa M, Jonesb A, Silversteinc S, Daniulaityted R, LoVecchiod F medRxiv. 2024; .

PMID: 39252927 PMC: 11383463. DOI: 10.1101/2024.08.27.24312661.


Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et....

Bakouni H, Sharafi H, Drouin S, Fortin R, Marsan S, Brissette S Can J Psychiatry. 2023; 69(4):252-263.

PMID: 37899716 PMC: 10924583. DOI: 10.1177/07067437231210796.


Supervised smoking facility access, harm reduction practices, and substance use changes during the COVID-19 pandemic: a community-engaged cross-sectional study.

Van Draanen J, Hamilton J, Morgan J, Maxwell S, Taylor T, Richardson L Harm Reduct J. 2023; 20(1):101.

PMID: 37525168 PMC: 10388471. DOI: 10.1186/s12954-023-00825-7.


References
1.
Ciccarone D . Fentanyl in the US heroin supply: A rapidly changing risk environment. Int J Drug Policy. 2017; 46:107-111. PMC: 5742018. DOI: 10.1016/j.drugpo.2017.06.010. View

2.
Robinson S, Sobell L, Sobell M, Leo G . Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav. 2013; 28(1):154-62. DOI: 10.1037/a0030992. View

3.
Korf D, van Ginkel P, Benschop A . How to find non-dependent opiate users: a comparison of sampling methods in a field study of opium and heroin users. Int J Drug Policy. 2009; 21(3):215-21. DOI: 10.1016/j.drugpo.2009.08.005. View

4.
Forman R, Svikis D, Montoya I, Blaine J . Selection of a substance use disorder diagnostic instrument by the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat. 2004; 27(1):1-8. PMC: 2668155. DOI: 10.1016/j.jsat.2004.03.012. View

5.
Silverstein S, Daniulaityte R, Miller S, Martins S, Carlson R . On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine. Drug Alcohol Depend. 2020; 210:107958. PMC: 7190448. DOI: 10.1016/j.drugalcdep.2020.107958. View